VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q43175898 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000328.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q43175898‏
024 ‎‡a 0000-0001-8088-566X‏ ‎‡2 orcid‏
024 ‎‡a 57203272912‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q43175898‏
100 0 ‎‡a Kenneth J Smith‏ ‎‡9 es‏ ‎‡9 sl‏ ‎‡9 ast‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a কেনেথ জে স্মিথ‏ ‎‡c গবেষক‏ ‎‡9 bn‏
400 0 ‎‡a Kenneth J Smith‏ ‎‡c researcher (ORCID 0000-0001-8088-566X)‏ ‎‡9 en‏
400 0 ‎‡a Kenneth J Smith‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A cost-effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children‏
670 ‎‡a Author's A cost-effectiveness analysis of positron emission tomography-computed tomography surveillance versus up-front neck dissection for management of the neck for N2 disease after chemoradiotherapy.‏
670 ‎‡a Author's A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children.‏
670 ‎‡a Author's A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP).‏
670 ‎‡a Author's A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult‏
670 ‎‡a Author's A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population‏
670 ‎‡a Author's Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis‏
670 ‎‡a Author's Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.‏
670 ‎‡a Author's An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis‏
670 ‎‡a Author's Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective.‏
670 ‎‡a Author's Automated Communication Tools and Computer-Based Medication Reconciliation to Decrease Hospital Discharge Medication Errors.‏
670 ‎‡a Author's Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis‏
670 ‎‡a Author's Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer‏
670 ‎‡a Author's Contraceptive effectiveness of immediate compared with delayed insertion of intrauterine devices after abortion: a decision analysis‏
670 ‎‡a Author's Cost comparisons between home- and clinic-based testing for sexually transmitted diseases in high-risk young women‏
670 ‎‡a Author's Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007.‏
670 ‎‡a Author's Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults‏
670 ‎‡a Author's Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults‏
670 ‎‡a Author's Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old‏
670 ‎‡a Author's Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis‏
670 ‎‡a Author's Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults‏
670 ‎‡a Author's Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers‏
670 ‎‡a Author's Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population‏
670 ‎‡a Author's Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine‏
670 ‎‡a Author's Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies.‏
670 ‎‡a Author's Cost effectiveness of an internet-delivered lifestyle intervention in primary care patients with high cardiovascular risk.‏
670 ‎‡a Author's Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds‏
670 ‎‡a Author's Cost-effectiveness of endoscopic sphenopalatine artery ligation versus nasal packing as first-line treatment for posterior epistaxis‏
670 ‎‡a Author's Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients‏
670 ‎‡a Author's Cost-effectiveness of implantable cardioverter-defibrillators in children with dilated cardiomyopathy.‏
670 ‎‡a Author's Cost-effectiveness of implementing the chronic care model for diabetes care in a military population.‏
670 ‎‡a Author's Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis‏
670 ‎‡a Author's Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.‏
670 ‎‡a Author's Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine‏
670 ‎‡a Author's Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism‏
670 ‎‡a Author's Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism‏
670 ‎‡a Author's Cost-effectiveness of newer treatment strategies for influenza‏
670 ‎‡a Author's Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.‏
670 ‎‡a Author's Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.‏
670 ‎‡a Author's Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults‏
670 ‎‡a Author's Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic.‏
670 ‎‡a Author's Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years‏
670 ‎‡a Author's Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations‏
670 ‎‡a Author's Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults‏
670 ‎‡a Author's Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia‏
670 ‎‡a Author's Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States‏
670 ‎‡a Author's Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model‏
670 ‎‡a Author's Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older‏
670 ‎‡a Author's Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.‏
670 ‎‡a Author's Cost-identification analysis of total laryngectomy: an itemized approach to hospital costs‏
670 ‎‡a Author's Cost-Utility Analysis of von Willebrand Disease Screening in Adolescents with Menorrhagia‏
670 ‎‡a Author's Direct Paramedic Transport of Acute Myocardial Infarction Patients to Percutaneous Coronary Intervention Centers: A Decision Analysis‏
670 ‎‡a Author's Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study‏
670 ‎‡a Author's Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study‏
670 ‎‡a Author's Economic Evaluation of Standing Order Programs for Pneumococcal Vaccination of Hospitalized Elderly Patients‏
670 ‎‡a Author's Economic model for emergency use authorization of intravenous peramivir‏
670 ‎‡a Author's Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza‏
670 ‎‡a Author's Economics of influenza vaccine administration timing for children.‏
670 ‎‡a Author's Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups‏
670 ‎‡a Author's Exploring the potential public health benefits of universal influenza vaccine‏
670 ‎‡a Author's Forecasting the economic value of an Enterovirus 71‏
670 ‎‡a Author's Forecasting the economic value of an Enterovirus 71 (EV71) vaccine‏
670 ‎‡a Author's Gene therapy in hemophilia A: a cost-effectiveness analysis‏
670 ‎‡a Author's Herpes Zoster Vaccine and Older Adults‏
670 ‎‡a Author's Hospitalization for Pelvic Inflammatory Disease: A Cost-Effectiveness Analysis‏
670 ‎‡a Author's Impact of seasonal influenza vaccination in the presence of vaccine interference‏
670 ‎‡a Author's Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.‏
670 ‎‡a Author's Incremental cost-effectiveness of various monthly doses of vardenafil‏
670 ‎‡a Author's Information primary care physicians want to receive about their hospitalized patients.‏
670 ‎‡a Author's InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence‏
670 ‎‡a Author's Managing mesh exposure following vaginal prolapse repair: a decision analysis comparing conservative versus surgical treatment‏
670 ‎‡a Author's Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults‏
670 ‎‡a Author's Oral anticoagulation strategies after a first idiopathic venous thromboembolic event‏
670 ‎‡a Author's Pharmacoeconomics of antiviral therapies for Herpes zoster infections‏
670 ‎‡a Author's Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations‏
670 ‎‡a Author's Potential Consequences of Not Using Live Attenuated Influenza Vaccine‏
670 ‎‡a Author's Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults‏
670 ‎‡a Author's Prediction of pelvic inflammatory disease among young, single, sexually active women‏
670 ‎‡a Author's Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization‏
670 ‎‡a Author's Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis‏
670 ‎‡a Author's Quality of life utilities for pelvic inflammatory disease health states.‏
670 ‎‡a Author's Quality-of-Life Utility Values for???Erectile Function and Sildenafil Treatment‏
670 ‎‡a Author's Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S.‏
670 ‎‡a Author's Reliability of laparoscopic compared with hysteroscopic sterilization at 1 year: a decision analysis‏
670 ‎‡a Author's Reply to: Estimating the Full Value of High-Dose Influenza Vaccine‏
670 ‎‡a Author's Retropubic and transobturator midurethral slings: a decision analysis to compare outcomes including efficacy and complications‏
670 ‎‡a Author's Screening cardiac surgery patients for MRSA: an economic computer model.‏
670 ‎‡a Author's Sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis‏
670 ‎‡a Author's Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.‏
670 ‎‡a Author's Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus?‏
670 ‎‡a Author's Teaching medical decision modeling: a qualitative description of student errors and curriculum responses‏
670 ‎‡a Author's The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: a Markov decision analysis approach‏
670 ‎‡a Author's The Cost-Effectiveness of Immediate Treatment, Percutaneous Biopsy and Active Surveillance for the Diagnosis of the Small Solid Renal Mass: Evidence From a Markov Model‏
670 ‎‡a Author's The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis‏
670 ‎‡a Author's The potential economic value of a hookworm vaccine‏
670 ‎‡a Author's The potential economic value of a Staphylococcus aureus vaccine for neonates‏
670 ‎‡a Author's The timing of influenza vaccination for older adults‏
670 ‎‡a Author's The timing of influenza vaccination for older adults (65 years and older).‏
670 ‎‡a Author's Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals‏
670 ‎‡a Author's To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling‏
670 ‎‡a Author's Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis‏
670 ‎‡a Author's Using thrombophilia testing to determine anticoagulation duration in pediatric thrombosis is not cost-effective‏
909 ‎‡a (orcid) 000000018088566x‏ ‎‡9 1‏
909 ‎‡a (scopus) 57203272912‏ ‎‡9 1‏
919 ‎‡a timingofinfluenzavaccinationforolderadults65yearsandolder‏ ‎‡A The timing of influenza vaccination for older adults (65 years and older).‏ ‎‡9 1‏
919 ‎‡a universalmethicillinresistantstaphylococcusaureusmrsasurveillanceforadultsathospitaladmissionaneconomicmodelandanalysis‏ ‎‡A Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofinfluenzavaccineforuschildrenliveattenuatedandinactivatedinfluenzavaccine‏ ‎‡A Cost Effectiveness of Influenza Vaccine for U.S. Children: Live Attenuated and Inactivated Influenza Vaccine‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofimplantablecardioverterdefibrillatorsinchildrenwithdilatedcardiomyopathy‏ ‎‡A Cost-effectiveness of implantable cardioverter-defibrillators in children with dilated cardiomyopathy.‏ ‎‡9 1‏
919 ‎‡a timingofinfluenzavaccinationforolderadults‏ ‎‡A The timing of influenza vaccination for older adults‏ ‎‡9 1‏
919 ‎‡a potentialeconomicvalueofahookwormvaccine‏ ‎‡A The potential economic value of a hookworm vaccine‏ ‎‡9 1‏
919 ‎‡a retropubicandtransobturatormidurethralslingsadecisionanalysistocompareoutcomesincludingefficacyandcomplications‏ ‎‡A Retropubic and transobturator midurethral slings: a decision analysis to compare outcomes including efficacy and complications‏ ‎‡9 1‏
919 ‎‡a shouldvascularsurgerypatientsbescreenedpreoperativelyformethicillinresistantstaphylococcusaureus‏ ‎‡A Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus?‏ ‎‡9 1‏
919 ‎‡a sequentialmedicationstrategiesforpostherpeticneuralgiaacosteffectivenessanalysis‏ ‎‡A Sequential medication strategies for postherpetic neuralgia: a cost-effectiveness analysis‏ ‎‡9 1‏
919 ‎‡a qualityoflifeutilityvaluesforerectilefunctionandsildenafiltreatment‏ ‎‡A Quality-of-Life Utility Values for???Erectile Function and Sildenafil Treatment‏ ‎‡9 1‏
919 ‎‡a prophylacticantibioticstopreventurinarytractinfectionduringcleanintermittentselfcatheterizationciscformanagementofvoidingdysfunctionafterprolapseandincontinencesurgeryadecisionanalysis‏ ‎‡A Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis‏ ‎‡9 1‏
919 ‎‡a prophylacticantibioticstopreventurinarytractinfectionduringcleanintermittentselfcatheterization‏ ‎‡A Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization‏ ‎‡9 1‏
919 ‎‡a contraceptiveeffectivenessofimmediatecomparedwithdelayedinsertionofintrauterinedevicesafterabortionadecisionanalysis‏ ‎‡A Contraceptive effectiveness of immediate compared with delayed insertion of intrauterine devices after abortion: a decision analysis‏ ‎‡9 1‏
919 ‎‡a pneumococcalvaccinationinadultsaged65yearscosteffectivenessandhealthimpactinuspopulations‏ ‎‡A Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations‏ ‎‡9 1‏
919 ‎‡a pharmacoeconomicsofantiviraltherapiesforherpeszosterinfections‏ ‎‡A Pharmacoeconomics of antiviral therapies for Herpes zoster infections‏ ‎‡9 1‏
919 ‎‡a predictionofpelvicinflammatorydiseaseamongyoungsinglesexuallyactivewomen‏ ‎‡A Prediction of pelvic inflammatory disease among young, single, sexually active women‏ ‎‡9 1‏
919 ‎‡a estimatingthecosteffectivenessofanationalprogramtoeliminatedisparitiesininfluenzavaccinationratesamongelderlyminoritygroups‏ ‎‡A Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups‏ ‎‡9 1‏
919 ‎‡a exploringthepotentialpublichealthbenefitsofuniversalinfluenzavaccine‏ ‎‡A Exploring the potential public health benefits of universal influenza vaccine‏ ‎‡9 1‏
919 ‎‡a hospitalizationforpelvicinflammatorydiseaseacosteffectivenessanalysis‏ ‎‡A Hospitalization for Pelvic Inflammatory Disease: A Cost-Effectiveness Analysis‏ ‎‡9 1‏
919 ‎‡a predictivemodeloftheeconomiceffectsofaninfluenzavaccineadjuvantfortheolderadult‏ ‎‡A A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult‏ ‎‡9 1‏
919 ‎‡a impactofseasonalinfluenzavaccinationinthepresenceofvaccineinterference‏ ‎‡A Impact of seasonal influenza vaccination in the presence of vaccine interference‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofavaccinetopreventherpeszosterandpostherpeticneuralgiainolderadults‏ ‎‡A Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults‏ ‎‡9 1‏
919 ‎‡a costeffectivenessanalysisofpositronemissiontomographycomputedtomographysurveillanceversusupfrontneckdissectionformanagementoftheneckforn2diseaseafterchemoradiotherapy‏ ‎‡A A cost-effectiveness analysis of positron emission tomography-computed tomography surveillance versus up-front neck dissection for management of the neck for N2 disease after chemoradiotherapy.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofadultpneumococcalvaccinationpoliciesinunderservedminoritiesaged5064yearscomparedtotheusgeneralpopulation‏ ‎‡A Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population‏ ‎‡9 1‏
919 ‎‡a incrementalcosteffectivenessofpharmacistmanagederythropoiesisstimulatingagentclinicsfornondialysisdependentchronickidneydiseasepatients‏ ‎‡A Incremental cost effectiveness of pharmacist-managed erythropoiesis-stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessandpublichealtheffectofinfluenzavaccinestrategiesforuselderlyadults‏ ‎‡A Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults‏ ‎‡9 1‏
919 ‎‡a directparamedictransportofacutemyocardialinfarctionpatientstopercutaneouscoronaryinterventioncentersadecisionanalysis‏ ‎‡A Direct Paramedic Transport of Acute Myocardial Infarction Patients to Percutaneous Coronary Intervention Centers: A Decision Analysis‏ ‎‡9 1‏
919 ‎‡a costidentificationanalysisoftotallaryngectomyanitemizedapproachtohospitalcosts‏ ‎‡A Cost-identification analysis of total laryngectomy: an itemized approach to hospital costs‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofprocalcitoninguidedantibioticuseincommunityacquiredpneumonia‏ ‎‡A Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofpneumococcalvaccinationpoliciesanduptakeprogramsinusolderpopulations‏ ‎‡A Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofpneumococcalvaccinationanduptakeimprovementprogramsinunderservedandgeneralpopulationadultsaged65years‏ ‎‡A Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofpharmacotherapyforthepreventionofmigraineamarkovmodelapplication‏ ‎‡A Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofpneumococcalandinfluenzavaccinationstandingorderprograms‏ ‎‡A Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofpneumococcalconjugatevaccinationinimmunocompromisedadults‏ ‎‡A Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofpneumococcalpolysaccharidevaccineamonghealthcareworkersduringaninfluenzapandemic‏ ‎‡A Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessoflowmolecularweightheparinfortreatmentofpulmonaryembolism‏ ‎‡A Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofprocalcitoninguidedantibiotictherapyforoutpatientmanagementofacuterespiratorytractinfectionsinadults‏ ‎‡A Cost-effectiveness of procalcitonin-guided antibiotic therapy for outpatient management of acute respiratory tract infections in adults‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofinfluenzavaccinechoicesinchildrenaged28yearsintheus‏ ‎‡A Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofscreeningforunhealthyalcoholusewithcarbohydratedeficienttransferrinresultsfromaliteraturebaseddecisionanalyticcomputermodel‏ ‎‡A Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofimplementingthechroniccaremodelfordiabetescareinamilitarypopulation‏ ‎‡A Cost-effectiveness of implementing the chronic care model for diabetes care in a military population.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofincreasingvaccinationinhighriskadultsaged1864yearsamodelbaseddecisionanalysis‏ ‎‡A Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofthe4pillarspracticetransformationprogramtoimprovevaccinationofadultsaged65andolder‏ ‎‡A Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofendoscopicsphenopalatinearteryligationversusnasalpackingas1linetreatmentforposteriorepistaxis‏ ‎‡A Cost-effectiveness of endoscopic sphenopalatine artery ligation versus nasal packing as first-line treatment for posterior epistaxis‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofvenousthromboembolismpharmacologicalprophylaxisintotalhipandkneereplacementasystematicreview‏ ‎‡A Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofalternativeoutpatientpelvicinflammatorydiseasetreatmentstrategies‏ ‎‡A Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofaninternetdeliveredlifestyleinterventioninprimarycarepatientswithhighcardiovascularrisk‏ ‎‡A Cost effectiveness of an internet-delivered lifestyle intervention in primary care patients with high cardiovascular risk.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofprogramstoeliminatedisparitiesinelderlyvaccinationratesintheunitedstates‏ ‎‡A Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States‏ ‎‡9 1‏
919 ‎‡a doeschoiceofinfluenzavaccinetypechangediseaseburdenandcosteffectivenessintheunitedstatesanagentbasedmodelingstudy‏ ‎‡A Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study‏ ‎‡9 1‏
919 ‎‡a economicevaluationofstandingorderprogramsforpneumococcalvaccinationofhospitalizedelderlypatients‏ ‎‡A Economic Evaluation of Standing Order Programs for Pneumococcal Vaccination of Hospitalized Elderly Patients‏ ‎‡9 1‏
919 ‎‡a costutilityanalysisofvonwillebranddiseasescreeninginadolescentswithmenorrhagia‏ ‎‡A Cost-Utility Analysis of von Willebrand Disease Screening in Adolescents with Menorrhagia‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofaprogramtoeliminatedisparitiesinpneumococcalvaccinationratesinelderlyminoritypopulationsanexploratoryanalysis‏ ‎‡A Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis‏ ‎‡9 1‏
919 ‎‡a modelingofcosteffectivenessofpneumococcalconjugatevaccinationstrategiesinusolderadults‏ ‎‡A Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults‏ ‎‡9 1‏
919 ‎‡a costeffectivenessandpublichealthimpactofalternativeinfluenzavaccinationstrategiesinhighriskadults‏ ‎‡A Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults‏ ‎‡9 1‏
919 ‎‡a costutilityanalysisoftreatmentforacutechildhoodidiopathicthrombocytopenicpurpuraitp‏ ‎‡A A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP).‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofaddingdecolonizationtoasurveillancestrategyofscreeningandisolationformethicillinresistantstaphylococcusaureuscarriers‏ ‎‡A Cost-effectiveness of adding decolonization to a surveillance strategy of screening and isolation for methicillin-resistant Staphylococcus aureus carriers‏ ‎‡9 1‏
919 ‎‡a doescosteffectivenessofinfluenzavaccinechoicevaryacrosstheusanagentbasedmodelingstudy‏ ‎‡A Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study‏ ‎‡9 1‏
919 ‎‡a economicsofinfluenzavaccineadministrationtimingforchildren‏ ‎‡A Economics of influenza vaccine administration timing for children.‏ ‎‡9 1‏
919 ‎‡a interstimsacralneuromodulationandbotoxbotulinumatoxinintradetrusorinjectionsforrefractoryurgeurinaryincontinence‏ ‎‡A InterStim Sacral Neuromodulation and Botox Botulinum-A Toxin Intradetrusor Injections for Refractory Urge Urinary Incontinence‏ ‎‡9 1‏
919 ‎‡a economicsofemployersponsoredworkplacevaccinationtopreventpandemicandseasonalinfluenza‏ ‎‡A Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza‏ ‎‡9 1‏
919 ‎‡a costeffectivenessanalysisofeffortstoreduceriskoftype2diabetesandcardiovasculardiseaseinsouthwesternpennsylvania2005‏ ‎‡A Cost-effectiveness analysis of efforts to reduce risk of type 2 diabetes and cardiovascular disease in southwestern Pennsylvania, 2005-2007.‏ ‎‡9 1‏
919 ‎‡a economicmodelforemergencyuseauthorizationofintravenousperamivir‏ ‎‡A Economic model for emergency use authorization of intravenous peramivir‏ ‎‡9 1‏
919 ‎‡a consolidationpaclitaxelismorecosteffectivethanbevacizumabfollowingupfronttreatmentofadvancedepithelialovariancancer‏ ‎‡A Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer‏ ‎‡9 1‏
919 ‎‡a alternativestrategiesforadultpneumococcalpolysaccharidevaccinationacosteffectivenessanalysis‏ ‎‡A Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofnewertreatmentstrategiesforinfluenza‏ ‎‡A Cost-effectiveness of newer treatment strategies for influenza‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofdualinfluenzaandpneumococcalvaccinationin50yearolds‏ ‎‡A Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds‏ ‎‡9 1‏
919 ‎‡a automatedcommunicationtoolsandcomputerbasedmedicationreconciliationtodecreasehospitaldischargemedicationerrors‏ ‎‡A Automated Communication Tools and Computer-Based Medication Reconciliation to Decrease Hospital Discharge Medication Errors.‏ ‎‡9 1‏
919 ‎‡a costcomparisonsbetweenhomeandclinicbasedtestingforsexuallytransmitteddiseasesinhighriskyoungwomen‏ ‎‡A Cost comparisons between home- and clinic-based testing for sexually transmitted diseases in high-risk young women‏ ‎‡9 1‏
919 ‎‡a anticoagulationinambulatorycancerpatientswithnoindicationforprophylacticortherapeuticanticoagulationacosteffectivenessanalysisfromausperspective‏ ‎‡A Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective.‏ ‎‡9 1‏
919 ‎‡a predictivemodeloftheeconomiceffectsofaninfluenzavaccineadjuvantfortheolderadultage65andoverpopulation‏ ‎‡A A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population‏ ‎‡9 1‏
919 ‎‡a interventiontoimprovepneumococcalvaccinationuptakeinhighrisk5064yearoldsvsexpandedagebasedrecommendationsanexploratorycosteffectivenessanalysis‏ ‎‡A An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis‏ ‎‡9 1‏
919 ‎‡a incrementalcosteffectivenessofvariousmonthlydosesofvardenafil‏ ‎‡A Incremental cost-effectiveness of various monthly doses of vardenafil‏ ‎‡9 1‏
919 ‎‡a agerevaccinationandtoleranceeffectsonpneumococcalvaccinationstrategiesintheelderlyacosteffectivenessanalysis‏ ‎‡A Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis‏ ‎‡9 1‏
919 ‎‡a forecastingtheeconomicvalueofanenterovirus71‏ ‎‡A Forecasting the economic value of an Enterovirus 71‏ ‎‡9 1‏
919 ‎‡a herpeszostervaccineandolderadults‏ ‎‡A Herpes Zoster Vaccine and Older Adults‏ ‎‡9 1‏
919 ‎‡a oralanticoagulationstrategiesaftera1idiopathicvenousthromboembolicevent‏ ‎‡A Oral anticoagulation strategies after a first idiopathic venous thromboembolic event‏ ‎‡9 1‏
919 ‎‡a potentialconsequencesofnotusingliveattenuatedinfluenzavaccine‏ ‎‡A Potential Consequences of Not Using Live Attenuated Influenza Vaccine‏ ‎‡9 1‏
919 ‎‡a costutilityanalysisof5strategiesforthemanagementofacuteotitismediainchildren‏ ‎‡A A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofapracticebasedinterventiontoimprovevaccinationratesinadultslessthan65yearsold‏ ‎‡A Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old‏ ‎‡9 1‏
919 ‎‡a potentialcosteffectivenessofauniversalinfluenzavaccineinolderadults‏ ‎‡A Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older Adults‏ ‎‡9 1‏
919 ‎‡a qualityoflifeutilitiesforpelvicinflammatorydiseasehealthstates‏ ‎‡A Quality of life utilities for pelvic inflammatory disease health states.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessanalysisofcoagulationtestingpriortotonsillectomyandadenoidectomyinchildren‏ ‎‡A A cost-effectiveness analysis of coagulation testing prior to tonsillectomy and adenoidectomy in children‏ ‎‡9 1‏
919 ‎‡a racialdisparitiesinadultpneumococcalvaccinationindicationsandpneumococcalhospitalizationsintheus‏ ‎‡A Racial Disparities in Adult Pneumococcal Vaccination Indications and Pneumococcal Hospitalizations in the U.S.‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofadultvaccinationstrategiesusingpneumococcalconjugatevaccinecomparedwithpneumococcalpolysaccharidevaccine‏ ‎‡A Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine‏ ‎‡9 1‏
919 ‎‡a reliabilityoflaparoscopiccomparedwithhysteroscopicsterilizationat1yearadecisionanalysis‏ ‎‡A Reliability of laparoscopic compared with hysteroscopic sterilization at 1 year: a decision analysis‏ ‎‡9 1‏
919 ‎‡a screeningcardiacsurgerypatientsformrsaaneconomiccomputermodel‏ ‎‡A Screening cardiac surgery patients for MRSA: an economic computer model.‏ ‎‡9 1‏
919 ‎‡a replytoestimatingthefullvalueofhighdoseinfluenzavaccine‏ ‎‡A Reply to: Estimating the Full Value of High-Dose Influenza Vaccine‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofcommunitybasedscreeningfororalcancerinhighriskmalesintheunitedstatesamarkovdecisionanalysisapproach‏ ‎‡A The cost-effectiveness of community-based screening for oral cancer in high-risk males in the United States: a Markov decision analysis approach‏ ‎‡9 1‏
919 ‎‡a teachingmedicaldecisionmodelingaqualitativedescriptionofstudenterrorsandcurriculumresponses‏ ‎‡A Teaching medical decision modeling: a qualitative description of student errors and curriculum responses‏ ‎‡9 1‏
919 ‎‡a shouldfemalerelativesoffactor5leidencarriersbescreenedpriortooralcontraceptiveuseacosteffectivenessanalysis‏ ‎‡A Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.‏ ‎‡9 1‏
919 ‎‡a genetherapyinhemophiliaaacosteffectivenessanalysis‏ ‎‡A Gene therapy in hemophilia A: a cost-effectiveness analysis‏ ‎‡9 1‏
919 ‎‡a potentialeconomicvalueofastaphylococcusaureusvaccineforneonates‏ ‎‡A The potential economic value of a Staphylococcus aureus vaccine for neonates‏ ‎‡9 1‏
919 ‎‡a hiddensocietalcostofantibioticresistanceperantibioticprescribedintheunitedstatesanexploratoryanalysis‏ ‎‡A The hidden societal cost of antibiotic resistance per antibiotic prescribed in the United States: an exploratory analysis‏ ‎‡9 1‏
919 ‎‡a forecastingtheeconomicvalueofanenterovirus71ev71vaccine‏ ‎‡A Forecasting the economic value of an Enterovirus 71 (EV71) vaccine‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofimmediatetreatmentpercutaneousbiopsyandactivesurveillanceforthediagnosisofthesmallsolidrenalmassevidencefromamarkovmodel‏ ‎‡A The Cost-Effectiveness of Immediate Treatment, Percutaneous Biopsy and Active Surveillance for the Diagnosis of the Small Solid Renal Mass: Evidence From a Markov Model‏ ‎‡9 1‏
919 ‎‡a costeffectivenessoflowmolecularweightheparinforsecondaryprophylaxisofcancerrelatedvenousthromboembolism‏ ‎‡A Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism‏ ‎‡9 1‏
919 ‎‡a compressedinfluenzavaccinationinusolderadultsadecisionanalysis‏ ‎‡A Compressed Influenza Vaccination in U.S. Older Adults: A Decision Analysis‏ ‎‡9 1‏
919 ‎‡a usingthrombophiliatestingtodetermineanticoagulationdurationinpediatricthrombosisisnotcosteffective‏ ‎‡A Using thrombophilia testing to determine anticoagulation duration in pediatric thrombosis is not cost-effective‏ ‎‡9 1‏
919 ‎‡a totestortotreatananalysisofinfluenzatestingandantiviraltreatmentstrategiesusingeconomiccomputermodeling‏ ‎‡A To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling‏ ‎‡9 1‏
919 ‎‡a costeffectivenessofguidelinesforinsertionofinferiorvenacavafiltersinhighrisktraumapatients‏ ‎‡A Cost-effectiveness of guidelines for insertion of inferior vena cava filters in high-risk trauma patients‏ ‎‡9 1‏
919 ‎‡a timefromsexuallytransmittedinfectionacquisitiontopelvicinflammatorydiseasedevelopmentinfluenceonthecosteffectivenessofdifferentscreeningintervals‏ ‎‡A Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals‏ ‎‡9 1‏
919 ‎‡a managingmeshexposurefollowingvaginalprolapserepairadecisionanalysiscomparingconservativeversussurgicaltreatment‏ ‎‡A Managing mesh exposure following vaginal prolapse repair: a decision analysis comparing conservative versus surgical treatment‏ ‎‡9 1‏
919 ‎‡a informationprimarycarephysicianswanttoreceiveabouttheirhospitalizedpatients‏ ‎‡A Information primary care physicians want to receive about their hospitalized patients.‏ ‎‡9 1‏
943 ‎‡a 200x‏ ‎‡A 2007‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 LC|n 93045168‏
996 ‎‡2 CAOONL|ncf10730539‏
996 ‎‡2 ISNI|000000003722819X‏
996 ‎‡2 NUKAT|n 2014191324‏
996 ‎‡2 DNB|134845315‏
996 ‎‡2 ISNI|0000000033427765‏
996 ‎‡2 ISNI|0000000040389760‏
996 ‎‡2 BNF|16672515‏
996 ‎‡2 NII|DA02368745‏
996 ‎‡2 LC|nb2013019294‏
996 ‎‡2 ISNI|0000000026660198‏
996 ‎‡2 ISNI|0000000114585298‏
996 ‎‡2 SUDOC|187198721‏
996 ‎‡2 SUDOC|240876881‏
996 ‎‡2 W2Z|1615360582159‏
996 ‎‡2 ISNI|0000000033161522‏
996 ‎‡2 LC|no2017116026‏
996 ‎‡2 NUKAT|n 2018040078‏
996 ‎‡2 LC|n 87129157‏
996 ‎‡2 NTA|068613733‏
996 ‎‡2 LC|nb2016003838‏
996 ‎‡2 SUDOC|164716718‏
996 ‎‡2 LC|n 87154340‏
996 ‎‡2 LC|n 92078508‏
996 ‎‡2 LC|n 90669180‏
996 ‎‡2 ISNI|0000000082347462‏
996 ‎‡2 ISNI|0000000499837619‏
996 ‎‡2 ISNI|000000041018427X‏
996 ‎‡2 LC|no 92009961‏
996 ‎‡2 ISNI|0000000369518476‏
996 ‎‡2 NKC|jcu2013767141‏
996 ‎‡2 LC|n 90624951‏
996 ‎‡2 ISNI|0000000029357477‏
996 ‎‡2 LC|n 84133007‏
996 ‎‡2 LC|n 95000557‏
996 ‎‡2 NDL|00832361‏
996 ‎‡2 NII|DA0284970X‏
996 ‎‡2 NTA|241526051‏
996 ‎‡2 LC|n 2021000827‏
996 ‎‡2 LC|n 84120882‏
996 ‎‡2 LC|n 84003121‏
996 ‎‡2 ISNI|0000000110770445‏
996 ‎‡2 NTA|070160961‏
996 ‎‡2 ISNI|0000000383293306‏
996 ‎‡2 RERO|A003839563‏
996 ‎‡2 LC|no2022090268‏
996 ‎‡2 ISNI|0000000022879432‏
996 ‎‡2 NTA|068180756‏
996 ‎‡2 ISNI|0000000379434647‏
996 ‎‡2 ISNI|0000000387932830‏
996 ‎‡2 NLA|000035507036‏
996 ‎‡2 LC|n 2023055822‏
996 ‎‡2 NLA|000035507039‏
996 ‎‡2 LC|n 85335654‏
996 ‎‡2 LC|no2014026403‏
996 ‎‡2 J9U|987007280443905171‏
996 ‎‡2 JPG|500036502‏
996 ‎‡2 BNF|15981192‏
996 ‎‡2 ISNI|0000000039709675‏
996 ‎‡2 NUKAT|n 95005655‏
996 ‎‡2 ISNI|000000003235201X‏
996 ‎‡2 BNF|11925032‏
996 ‎‡2 NII|DA17665777‏
996 ‎‡2 ISNI|0000000063386124‏
996 ‎‡2 CAOONL|ncf11029819‏
996 ‎‡2 LC|n 2003073710‏
996 ‎‡2 DNB|1061473538‏
996 ‎‡2 LC|n 2018018889‏
996 ‎‡2 ISNI|0000000076697087‏
996 ‎‡2 LC|n 87937280‏
996 ‎‡2 LC|n 87937281‏
996 ‎‡2 ISNI|0000000115595041‏
996 ‎‡2 J9U|987007350464905171‏
996 ‎‡2 ISNI|0000000031144032‏
996 ‎‡2 SZ|1032553804‏
996 ‎‡2 LC|n 88275033‏
996 ‎‡2 LC|n 92059593‏
996 ‎‡2 SUDOC|125842546‏
996 ‎‡2 BIBSYS|90261466‏
996 ‎‡2 BNF|16993322‏
996 ‎‡2 LC|n 86868492‏
996 ‎‡2 ISNI|0000000082197150‏
996 ‎‡2 LC|n 85139803‏
996 ‎‡2 LIH|LNB:C_k__s_5;=B2‏
996 ‎‡2 LC|n 91098182‏
996 ‎‡2 LC|n 85022743‏
996 ‎‡2 ISNI|0000000123181105‏
996 ‎‡2 J9U|987007597711805171‏
996 ‎‡2 DNB|1089153139‏
996 ‎‡2 NTA|317850342‏
996 ‎‡2 ISNI|0000000066594551‏
996 ‎‡2 BIBSYS|90803156‏
996 ‎‡2 NSK|000064856‏
996 ‎‡2 LC|n 82029528‏
996 ‎‡2 JPG|500227329‏
996 ‎‡2 NKC|skuk0002112‏
996 ‎‡2 CAOONL|ncf10991518‏
996 ‎‡2 DNB|1141921421‏
996 ‎‡2 J9U|987007429727405171‏
996 ‎‡2 SIMACOB|135397987‏
996 ‎‡2 CAOONL|ncf11286470‏
996 ‎‡2 LC|n 88183334‏
996 ‎‡2 CAOONL|ncf10336504‏
996 ‎‡2 DBC|87097992174727‏
996 ‎‡2 BIBSYS|9066568‏
996 ‎‡2 BIBSYS|5061374‏
996 ‎‡2 ISNI|0000000063027463‏
996 ‎‡2 NKC|xx0043495‏
996 ‎‡2 CAOONL|ncf10139663‏
996 ‎‡2 ISNI|0000000107315900‏
996 ‎‡2 LC|n 83013140‏
996 ‎‡2 JPG|500109768‏
996 ‎‡2 ISNI|0000000107174319‏
996 ‎‡2 LC|n 2013036471‏
996 ‎‡2 CAOONL|ncf10117911‏
996 ‎‡2 DBC|87097992174654‏
996 ‎‡2 ISNI|0000000081405253‏
996 ‎‡2 BIBSYS|13041812‏
996 ‎‡2 PLWABN|9811719504305606‏
996 ‎‡2 LC|n 92006675‏
996 ‎‡2 NTA|102592004‏
996 ‎‡2 ISNI|0000000043414925‏
996 ‎‡2 LC|n 2011047865‏
996 ‎‡2 JPG|500096477‏
996 ‎‡2 J9U|987007375816805171‏
996 ‎‡2 LC|no2004097816‏
996 ‎‡2 LC|no2018155967‏
996 ‎‡2 NUKAT|n 2005112602‏
996 ‎‡2 ISNI|0000000038441355‏
996 ‎‡2 ISNI|0000000028520252‏
996 ‎‡2 J9U|987007359215605171‏
996 ‎‡2 ISNI|0000000032086188‏
996 ‎‡2 BIBSYS|90157611‏
996 ‎‡2 CAOONL|ncf10539390‏
996 ‎‡2 RERO|A011158733‏
996 ‎‡2 ISNI|0000000072688220‏
996 ‎‡2 SUDOC|235028347‏
996 ‎‡2 SUDOC|030461200‏
996 ‎‡2 LC|n 86807279‏
996 ‎‡2 BNF|15500086‏
996 ‎‡2 NTA|157169707‏
996 ‎‡2 ISNI|0000000000879511‏
996 ‎‡2 BLBNB|000357481‏
996 ‎‡2 LC|no2003093406‏
996 ‎‡2 CAOONL|ncf10120079‏
996 ‎‡2 BNF|16248405‏
996 ‎‡2 NII|DA01738328‏
996 ‎‡2 DNB|1089777493‏
996 ‎‡2 ISNI|0000000083316940‏
996 ‎‡2 DNB|170666352‏
996 ‎‡2 LC|nb2006006700‏
996 ‎‡2 CAOONL|ncf10358043‏
996 ‎‡2 ISNI|0000000498512927‏
996 ‎‡2 CAOONL|ncf10193211‏
996 ‎‡2 SUDOC|279958595‏
996 ‎‡2 BIBSYS|90004946‏
996 ‎‡2 ISNI|0000000021598436‏
996 ‎‡2 SUDOC|074611658‏
996 ‎‡2 NTA|271268891‏
996 ‎‡2 ISNI|0000000123277086‏
996 ‎‡2 SUDOC|251547019‏
996 ‎‡2 LC|no2006079439‏
996 ‎‡2 LC|n 89652656‏
996 ‎‡2 PTBNP|576924‏
996 ‎‡2 RERO|A026883097‏
996 ‎‡2 BIBSYS|4075788‏
996 ‎‡2 BNF|17079528‏
996 ‎‡2 LC|no2007120005‏
996 ‎‡2 NUKAT|n 99043852‏
996 ‎‡2 LC|n 50025224‏
996 ‎‡2 LC|n 50025225‏
996 ‎‡2 ISNI|0000000496292203‏
996 ‎‡2 SUDOC|093633610‏
996 ‎‡2 ISNI|0000000067126258‏
996 ‎‡2 LC|nb2013002799‏
996 ‎‡2 ISNI|0000000115120767‏
996 ‎‡2 SUDOC|25673576X‏
996 ‎‡2 DNB|1078986258‏
996 ‎‡2 ISNI|0000000025202523‏
996 ‎‡2 BIBSYS|90103068‏
996 ‎‡2 ISNI|0000000123861426‏
996 ‎‡2 NDL|001093839‏
996 ‎‡2 NTA|401466019‏
996 ‎‡2 ISNI|0000000045092800‏
996 ‎‡2 DNB|102207380X‏
996 ‎‡2 ISNI|0000000109201368‏
996 ‎‡2 ISNI|0000000393337544‏
996 ‎‡2 ISNI|0000000110726196‏
996 ‎‡2 LC|no2015086901‏
996 ‎‡2 LC|n 78096478‏
996 ‎‡2 ISNI|0000000046287722‏
996 ‎‡2 NTA|074718665‏
996 ‎‡2 LC|n 80002506‏
996 ‎‡2 NKC|ctu2018983334‏
996 ‎‡2 LC|n 00122222‏
996 ‎‡2 ISNI|0000000026897750‏
996 ‎‡2 LC|nb2012012142‏
996 ‎‡2 LC|n 95095217‏
996 ‎‡2 NYNYRILM|65728‏
996 ‎‡2 NTA|068429878‏
996 ‎‡2 LC|n 88670732‏
996 ‎‡2 BIBSYS|9066459‏
996 ‎‡2 LC|n 85801524‏
996 ‎‡2 SUDOC|185164684‏
996 ‎‡2 CAOONL|ncf10017020‏
996 ‎‡2 ISNI|0000000110815818‏
996 ‎‡2 LC|n 79109413‏
996 ‎‡2 SUDOC|113420080‏
996 ‎‡2 J9U|987012722491905171‏
996 ‎‡2 LC|no2004058494‏
996 ‎‡2 LC|n 82267742‏
996 ‎‡2 NTA|074305042‏
996 ‎‡2 SUDOC|031606695‏
996 ‎‡2 BLBNB|000985589‏
996 ‎‡2 J9U|987007461319605171‏
996 ‎‡2 LC|n 96034700‏
996 ‎‡2 BIBSYS|90346689‏
996 ‎‡2 LC|n 90641440‏
996 ‎‡2 BNC|981058616449006706‏
996 ‎‡2 NII|DA03167250‏
996 ‎‡2 J9U|987012502679205171‏
996 ‎‡2 DNB|1177173921‏
996 ‎‡2 BNF|14490400‏
996 ‎‡2 SUDOC|085836907‏
996 ‎‡2 RERO|A003839579‏
996 ‎‡2 NKC|jn20001227097‏
996 ‎‡2 BNF|16915828‏
996 ‎‡2 NKC|jx20041102005‏
996 ‎‡2 DNB|1053164912‏
996 ‎‡2 LC|n 87872169‏
996 ‎‡2 LC|n 2005080835‏
996 ‎‡2 ISNI|0000000500337516‏
996 ‎‡2 ISNI|000000043030892X‏
996 ‎‡2 NLA|000035507043‏
996 ‎‡2 NLA|000035507048‏
996 ‎‡2 ISNI|0000000076102653‏
996 ‎‡2 SELIBR|381933‏
996 ‎‡2 ISNI|0000000076443220‏
996 ‎‡2 ISNI|0000000027743745‏
996 ‎‡2 RERO|A027043255‏
996 ‎‡2 NLA|000035260002‏
996 ‎‡2 PLWABN|9811739335805606‏
996 ‎‡2 ISNI|0000000084426412‏
996 ‎‡2 NTA|067893929‏
996 ‎‡2 ISNI|0000000035164145‏
996 ‎‡2 LC|no2022088283‏
996 ‎‡2 ISNI|0000000031062643‏
996 ‎‡2 CAOONL|ncf12027590‏
996 ‎‡2 DNB|174075456‏
996 ‎‡2 LC|n 96052772‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏